[go: up one dir, main page]

DK200700656A - Piscirickettsia salmonis antigens and their use - Google Patents

Piscirickettsia salmonis antigens and their use Download PDF

Info

Publication number
DK200700656A
DK200700656A DK200700656A DKPA200700656A DK200700656A DK 200700656 A DK200700656 A DK 200700656A DK 200700656 A DK200700656 A DK 200700656A DK PA200700656 A DKPA200700656 A DK PA200700656A DK 200700656 A DK200700656 A DK 200700656A
Authority
DK
Denmark
Prior art keywords
vaccine
protein
recombinant polypeptide
cell
seq
Prior art date
Application number
DK200700656A
Other languages
Danish (da)
Inventor
Thiry Michel
Dheur Ingrid
Original Assignee
Thiry Michel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2004/003339 external-priority patent/WO2005035558A2/en
Priority claimed from IE20040674A external-priority patent/IE20040674A1/en
Application filed by Thiry Michel filed Critical Thiry Michel
Publication of DK200700656A publication Critical patent/DK200700656A/en
Priority to DK200900603A priority Critical patent/DK200900603A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (36)

1. Isoleret Ps-protein der omfatter mindst én af følgende: (a) en aminosyresekvens der omfatter en konservativ aminosyresubstitution, hvor aminosyresekvensen er valgt fra gruppen bestående af SEQ ID NO: 6, 8, 10, 12, 14, 16 og 18; og (b) en aminosyresekvens der er mindst 70% identisk med aminosyresekvensen ifølge SEQ ID NO: 6, 8, 10, 12, 14, 16 eller 18.An isolated Ps protein comprising at least one of the following: (a) an amino acid sequence comprising a conservative amino acid substitution wherein the amino acid sequence is selected from the group consisting of SEQ ID NOs: 6, 8, 10, 12, 14, 16 and 18; and (b) an amino acid sequence at least 70% identical to the amino acid sequence of SEQ ID NO: 6, 8, 10, 12, 14, 16 or 18. 2. Isoleret antigent fragment af Ps-proteinet ifølge krav 1.An isolated antigenic fragment of the Ps protein of claim 1. 3. Rekombinant polypeptid der omfatter aminosyresekvensen af Psproteinet ifølge krav 1 eller det antigene fragment ifølge krav 2.A recombinant polypeptide comprising the amino acid sequence of the P protein of claim 1 or the antigenic fragment of claim 2. 4. Rekombinant polypeptid ifølge krav 3, hvilket polypeptid er et kimært protein.The recombinant polypeptide of claim 3, which polypeptide is a chimeric protein. 5. Antistof som er rejst mod mindst ét af følgende: (a) det isolerede Psprotein ifølge krav 1; (b) det isolerede antigene fragment ifølge krav 2; (c) det rekombinante polypeptid ifølge krav 3; og (d) det rekombinante polypeptid ifølge krav 4.An antibody raised against at least one of the following: (a) the isolated P protein of claim 1; (b) the isolated antigenic fragment of claim 2; (c) the recombinant polypeptide of claim 3; and (d) the recombinant polypeptide of claim 4. 6. Isoleret eller rekombinant nukleinsyre der koder for mindst ét af følgende: (a) det isolerede Psprotein ifølge krav 1; (b) det isolerede antigene fragment ifølge krav 2; (c) det rekombinante polypeptid ifølge krav 3; og (d) det rekombinante polypeptid ifølge krav 4.An isolated or recombinant nucleic acid encoding at least one of the following: (a) the isolated P protein of claim 1; (b) the isolated antigenic fragment of claim 2; (c) the recombinant polypeptide of claim 3; and (d) the recombinant polypeptide of claim 4. 7. Nukleinsyreifølge krav 6 der omfatter en nukleotidsekvens som er valgt fra gruppen bestående af SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17 og SEQ ID NO:19.A nucleic acid sequence according to claim 6 comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 and SEQ ID NO: 19. 8. Nukleinsyre der hybridiserer til nukleotidsekvensen ifølge krav 7, hvor nukleinsyren omfatter mindst 12 nukleotider.A nucleic acid hybridizing to the nucleotide sequence of claim 7, wherein the nucleic acid comprises at least 12 nucleotides. 9. Ekspressionsvektor der omfatter nukleinsyren ifølge et hvilket som helst af kravene 6-8, og en transkriptionel kontrolsekvens hvor nukleinsyren er operativt bundet til den transkriptionelle kontrolsekvens.An expression vector comprising the nucleic acid of any one of claims 6-8, and a transcriptional control sequence wherein the nucleic acid is operably linked to the transcriptional control sequence. 10. Værtscelle der omfatter ekspressionsvektoren ifølge krav 9.A host cell comprising the expression vector of claim 9. 11. Fremgangsmåde til fremstilling af et rekombinant polypeptid, hvilken fremgangsmåde omfatter dyrkning af værtscellen ifølge krav 10 i et dyrkningsmedium, hvor værtscellen udtrykker den nukleinsyre der koder for det rekombinante polypeptid; og hvorved det rekombinante polypeptid frembringes.A method of producing a recombinant polypeptide, which comprises culturing the host cell of claim 10 in a culture medium, wherein the host cell expresses the nucleic acid encoding the recombinant polypeptide; and thereby producing the recombinant polypeptide. 12. Fremgangsmåde ifølge krav 11 hvor værtscellen er en E. coli-celle.The method of claim 11 wherein the host cell is an E. coli cell. 13. Fremgangsmåde til opnåelse af et oprenset rekombinant polypeptid, hvilken fremgangsmåde omfatter oprensning af det rekombinante polypeptid der er frembragt ved fremgangsmåden ifølge krav 11.A method of obtaining a purified recombinant polypeptide, which method comprises purifying the recombinant polypeptide produced by the method of claim 11. 14. Oprenset rekombinant polypeptid der er opnået ved fremgangsmåden ifølge krav 13.The purified recombinant polypeptide obtained by the method of claim 13. 15. Rekombinant Yersinia ruckeri-celle der omfatter nukleinsyren ifølge et hvilket som helst af kravene 6-8.A recombinant Yersinia ruckeri cell comprising the nucleic acid of any one of claims 6-8. 16. Vaccine der omfatter mindst ét af følgende: (a) det isolerede Psprotein ifølge krav 1; (b) det isolerede antigene fragment ifølge krav 2; (c) det rekombinante polypeptid ifølge krav 3; og (d) det rekombinante polypeptid ifølge krav 4.A vaccine comprising at least one of the following: (a) the isolated Pprotein of claim 1; (b) the isolated antigenic fragment of claim 2; (c) the recombinant polypeptide of claim 3; and (d) the recombinant polypeptide of claim 4. 17. Vaccine der omfatter nukleinsyren ifølge et hvilket som helst af kravene 6-8.A vaccine comprising the nucleic acid of any of claims 6-8. 18. Vaccine der omfatter den rekombinante Yersinia ruckeri-ce\\e ifølge krav 15.A vaccine comprising the recombinant Yersinia ruckerase according to claim 15. 19. Vaccine ifølge krav 18 der desuden omfatter Yersinia ruckeri-cellen med BCCM-deponeringsnr. LMG P-22044.The vaccine of claim 18 further comprising the Yersinia ruckeri cell with BCCM deposit no. LMG P-22044. 20. Vaccine ifølge krav 18 eller 19 der desuden omfatter Yersinia ruckeri-ceWen med BCCM-deponeringsnr. LMG P-22511.The vaccine according to claim 18 or 19, further comprising the Yersinia ruckeri cue with BCCM deposit no. LMG P-22511. 21. Vaccine ifølge krav 18, hvor den rekombinante Yersinia ruckeri-celle er et bakterin.The vaccine of claim 18, wherein the recombinant Yersinia ruckeri cell is a bacterin. 22. Vaccine ifølge krav 19 der desuden omfatter et bakterin i Yersinia ruckeri-cellen med BCCM-deponeringsnr. LMG P-22044.The vaccine of claim 19 further comprising a bacterium in the Yersinia ruckeri cell with BCCM deposit no. LMG P-22044. 23. Vaccine ifølge krav 21 eller 22 der desuden omfatter et bakterin i Yersinia ruckeri-cellen med BCCM-deponeringsnr. LMG P-22511.The vaccine of claim 21 or 22 further comprising a bacterin in the Yersinia ruckeri cell with BCCM deposit no. LMG P-22511. 24. Vaccine ifølge krav 16 der desuden omfatter et bakterin i Yersinia ruckeri-cellen med BCCM-deponeringsnr. LMG P-22044.The vaccine of claim 16, further comprising a bacterium in the Yersinia ruckeri cell with BCCM deposit no. LMG P-22044. 25. Vaccine ifølge et hvilket som helst af kravene 16-24, hvilken vaccine yderligere omfatter et antigen der er opnået fra et infektiøst pancreasnekrose (IPN)-virus.A vaccine according to any one of claims 16-24, further comprising an antigen obtained from an infectious pancreatic necrosis (IPN) virus. 26. Vaccine ifølge krav 25, hvor det antigen der er opnået fra IPN-virusset, er valgt fra gruppen bestående af VP2-var-proteinet og VP3-proteinet.The vaccine of claim 25, wherein the antigen obtained from the IPN virus is selected from the group consisting of the VP2 var protein and the VP3 protein. 27. Vaccine ifølge et hvilket som helst af kravene 16-24, hvilken vaccine yderligere omfatter både VP2-var-proteinet og VP3-proteinet fra infektiøst pancreasnekrose (IPN)-virus.A vaccine according to any one of claims 16-24, further comprising both the VP2 var protein and the VP3 protein from infectious pancreatic necrosis (IPN) virus. 28. Vaccine ifølge krav 27, hvor VP2-var-proteinet er opnået fra en transformeret Pichia pasfo/v's-celle, BCCM-deponeringsnr. IHEM 20069, og VP3-proteinet er opnået fra en transformeret Pichia pastoris-celle, BCCM-deponeringsnr. IHEM 20071.The vaccine of claim 27, wherein the VP2 var protein is obtained from a transformed Pichia pasfo / v's cell, BCCM deposit no. IHEM 20069, and the VP3 protein is obtained from a transformed Pichia pastoris cell, BCCM landfill no. IHEM 20071. 29. Vaccine ifølge krav 27, hvor VP2-var-proteinet er opnået fra en transformeret Pichia pastor/s-celle, BCCM-deponeringsnr. IHEM 20070, og VP3-proteinet er opnået fra en transformeret Pichia pastoris-celle, BCCM-deponeringsnr. IHEM 20072.A vaccine according to claim 27, wherein the VP2 var protein is obtained from a transformed Pichia pastor / s cell, BCCM deposit no. IHEM 20070, and the VP3 protein is obtained from a transformed Pichia pastoris cell, BCCM deposit no. IHEM 20072. 30. Vaccine ifølge et hvilket som helst af kravene 16-29, hvilken vaccine yderligere omfatter et antigen der er opnået fra Aeromonas salmonicida.A vaccine according to any one of claims 16-29, further comprising an antigen obtained from Aeromonas salmonicida. 31. Fremgangsmåde til beskyttelse af en fisk mod rickettsial septicemia hos laksefisk, hvilken fremgangsmåde omfatter administration af vaccinen ifølge et hvilket som helst af kravene 16-30 til fisken.A method of protecting a fish against rickettsial septicemia in salmonids, which method comprises administering the vaccine according to any one of claims 16-30 to the fish. 32. Fremgangsmåde ifølge krav 31 hvor fisken er en teleost.The method of claim 31 wherein the fish is a teleost. 33. Fremgangsmåde ifølge krav 32 hvor teleosten er en laksefisk.The method of claim 32 wherein the teleost is a salmonid. 34. Fremgangsmåde til beskyttelse af fisk mod rickettsial septicemia hos laksefisk og infektiøs pancreasnekrose, hvilken fremgangsmåde omfatter administration af vaccinen ifølge et hvilket som helst af kravene 25-30 til fisken.A method of protecting fish against rickettsial septicemia in salmonids and infectious pancreatic necrosis, which method comprises administering the vaccine according to any of claims 25-30 to the fish. 35. Fremgangsmåde ifølge krav 34 hvor fisken er en laksefisk.The method of claim 34 wherein the fish is a salmonid. 36. Fremgangsmåde ifølge krav 33 eller 35 hvor laksefisken er valgt fra gruppen bestående afen Salmo salar (atlantisk laks), en Oncorhynchus kisutch (coho-laks) og en Oncorhynchus mykiss (regnbueørred).The method of claim 33 or 35, wherein the salmon fish is selected from the group consisting of Salmo salar (Atlantic salmon), an Oncorhynchus kisutch (coho salmon) and an Oncorhynchus mykiss (rainbow trout).
DK200700656A 2004-10-01 2007-05-01 Piscirickettsia salmonis antigens and their use DK200700656A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK200900603A DK200900603A (en) 2004-10-01 2009-05-12 Piscirickettsia salmonis antigens and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2004/003339 WO2005035558A2 (en) 2003-10-07 2004-10-01 Piscirickettsia salmonis antigens and use thereof
IE20040674A IE20040674A1 (en) 2003-10-07 2004-10-05 Piscirickettsia salmonis antigens and use thereof

Publications (1)

Publication Number Publication Date
DK200700656A true DK200700656A (en) 2007-05-01

Family

ID=34965943

Family Applications (1)

Application Number Title Priority Date Filing Date
DK200700656A DK200700656A (en) 2004-10-01 2007-05-01 Piscirickettsia salmonis antigens and their use

Country Status (5)

Country Link
EP (1) EP1794185A1 (en)
AU (1) AU2005291622A1 (en)
CA (1) CA2615139A1 (en)
DK (1) DK200700656A (en)
WO (1) WO2006037383A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008337440B2 (en) * 2007-12-19 2013-05-02 Intervet International B.V. Vaccine antigens from Piscirickettsia salmonis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1282710B1 (en) * 2000-03-11 2008-03-05 Novartis AG Fish vaccine against piscirickettsia salmonis
WO2002038770A1 (en) * 2000-11-11 2002-05-16 The University Court Of The University Of Aberdeen Yeast derived vaccine against ipnv
CA2541464C (en) * 2003-10-07 2016-02-09 Michel Thiry Piscirickettsia salmonis antigens and use thereof

Also Published As

Publication number Publication date
WO2006037383A1 (en) 2006-04-13
WO2006037383A8 (en) 2007-12-21
EP1794185A1 (en) 2007-06-13
AU2005291622A1 (en) 2006-04-13
CA2615139A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
DK200801818A (en) Vaccine antigens from piscirickettsia salmonis
DK2560985T3 (en) Nucleic acid sequences of a fish viruses and their uses
CN1280504A (en) Vaccines with an LTB adjuvant
Zhu et al. Preliminary screening and immunogenicity analysis of antigenic epitopes of spring viremia of carp virus
Kim et al. Development of a recombinant protein vaccine based on cell-free protein synthesis for sevenband grouper Epinephelus septemfasciatus against viral nervous necrosis
Tan et al. Cloning, expression and protective capacity of 37 kDa outer membrane protein gene (ompH) of Pasteurella multocida serotype B: 2.
Harrison et al. An Overview of Vaccine Development Strategies for Columnaris‐Causing Bacteria in Cultured Fish
Cai et al. Immune response in Lutjanus erythropterus induced by the major outer membrane protein (OmpU) of Vibrio alginolyticus
CN101880647A (en) Recombinant Salmonella choleraesuis and bivalent genetic engineering vaccine and its application
CA2707919A1 (en) A subunit vaccine for aquaculture
US20250127873A1 (en) Compositions and methods for prevention of piscine myocarditis
DK200900603A (en) Piscirickettsia salmonis antigens and their use
EP1334197B1 (en) Yeast derived vaccine against ipnv
JP2025501740A (en) Use of interferon as an adjuvant in vaccines
DK200700656A (en) Piscirickettsia salmonis antigens and their use
WO2018066948A2 (en) Recombinant antigen protein composed of multiple epitopes and method for producing same
Kamalii et al. Advanced developments in fish vaccination
CN1909925A (en) an immune adjuvant
US20250263448A1 (en) Veterinary vaccines and methods for the treatment of pasteurella multocida infections in food production animals
RU2851230C2 (en) Vaccines against moritella viscosa
WO2024129791A1 (en) Methods of vaccine administration to salmonids
Papadopoulos et al. Fish vaccination
CA2624486A1 (en) Novel sea lice vaccine
AU2022419507A1 (en) Compositions and methods for expressing antigens on cell membrane
Estepa et al. Enhancement of fish mortality by rhabdovirus infection after immunization with a viral nucleoprotein peptide

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment